Overactive Bladder

Question 1

Preferences

Answer 1

Start with non-pharm therapies (pelvic floor, behavioral therapy)
B3RA are preferred but expensive and require failure or reasons to not use other agents
Antimuscarinics available

Question 2

Mirabegon

Answer 2

MOA: Beta 3 receptor agonist; relaxes detrusor SM during urine storage phase; increases bladder capacity
BOX: N/A
CON: n/a
ADR: HTN

Question 3

Vibegron

Answer 3

MOA: Beta 3 RA
BOX: N/A
CON: n/a
ADR: n/a

Question 4

Oxybutynin

Answer 4

MOA: Antimuscarinic; antispasmodic effect on SM. Increases bladder capacity, decreases uninhibited contractions, delays desire to void, decrease urgency and frequency
BOX: N/A
CON: NAG, urinary retention, gastric retention, or conditions w/severely decreased GI motility
ADR: Constipation, xerostomia, dizzy, drowsy

Question 5

Darifenacin

Answer 5

MOA: Muscarinic Antagonist
BOX: N/A
CON: NAG, urine retention, gastric retention, conds w/severely depressed GI
ADR: xerostomia and constipation

Question 6

Solifenacin

Answer 6

MOA: Muscarinic Antagonist
BOX: N/A
CON: MA’s
ADR: Constipation, xerostomia

Question 7

Tolterodine

Answer 7

MOA: MA
BOX: N/A
CON: MA
ADR: Xerostomia

Question 8

Trospium

Answer 8

MOA: MA
BOX: N/A
CON: MA
ADR: Xerostomia

Question 9

Fesoterodine

Answer 9

MOA: MA
BOX: N/A
CON: MA
ADR: Xerostomia